Clinical Trials

NCT Number: NCT04597359 Phase: Phase 2 Trial Summary: This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surv – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): ECOG-ACRIN Cancer Research Group|National […]

NCT Number: NCT04589468 Phase: NA Trial Summary: Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center Acronym:

NCT Number: NCT04550494 Phase: Phase 2 Trial Summary: This phase II trial studies if talazoparib works in patients with cancer that has spread to other places in the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) d – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

NCT Number: NCT04530552 Phase: Phase 2 Trial Summary: This phase IIa trial investigates the biomarker (plasma levels of PSA) of low-dose apalutamide in patients with prostate cancer confined in the prostate gland before surgery. Testo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

NCT Number: NCT04506567 Phase: Phase 1|Phase 2 Trial Summary: The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 that can be given without severe side e – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College […]

NCT Number: NCT04545957 Phase: Not Applicable Trial Summary: This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of r – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Dana-Farber Cancer Institute Acronym: JUMP

NCT Number: NCT04486755 Phase: Phase 1 Trial Summary: A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, sim – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Maryland, Baltimore Acronym:

NCT Number: NCT04478279 Phase: Phase 1|Phase 2 Trial Summary: This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in pati – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Sapience Therapeutics Acronym:

NCT Number: NCT04428788 Phase: Phase 1 Trial Summary: The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate canc – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Celgene Acronym:

NCT Number: NCT04465500 Phase: Phase 2 Trial Summary: This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Virginia Acronym: Prostate005